Bioregulators & Organ Support
Thymalin
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Immunity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 50 mg
Dosing window: Anytime
Receptor / target: Thymus
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Russian clinical protocol. 10 consecutive days. Can be administered at any time of day. Repeat every 6 months. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: Quarterly Low-Dose Maintenance Protocol (Goal: sustained year-round thymopoietic support with reduced per-cycle intensity; preferred for subjects with well-maintained immune function seeking longevity maintenance rather than active immunosenescence reversal)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (Q1) | 5mg 1x daily | Half-dose intensive course. Baseline lymphocyte subset panel (CD3/CD4/CD8/NK/naive T-cell) before first quarterly cycle. |
| Days 1-10 (Q2) | 5mg 1x daily | Repeat quarterly. No washout panel required between quarterly cycles in healthy subjects. |
| Days 1-10 (Q3) | 5mg 1x daily | Continue quarterly. |
| Days 1-10 (Q4) | 5mg 1x daily | Annual lymphocyte subset panel at Q4 completion to assess cumulative thymopoietic response. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Intensive Immunosenescence Reversal Protocol (Goal: maximum thymic restoration for subjects with confirmed profound immunosenescence, low CD4+ count, severely reduced naive T-cell output, or recurrent infections; accelerated initial loading)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (Course 1) | 10mg 1x daily | First intensive course. Baseline lymphocyte subset panel (CD3, CD4, CD8, CD45RA naive T-cells, NK cells) required. If CD4+ < 300 or naive T-cell fraction < 10%, this double-course protocol is indicated. |
| Days 21-30 (Course 2) | 10mg 1x daily | 10-day washout between courses, then second full-dose course. Double-course loading for severe immunosenescence. Lymphocyte panel recheck before Course 2 initiation. |
| Days 91-100 (Course 3) | 10mg 1x daily | 3-month interval maintenance course. After the initial double loading, return to standard biannual schedule if immune markers trending toward normal. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3: Pre-Vaccination Immune Priming Protocol (Goal: maximize vaccine immunogenicity by restoring naive T-cell output and T-cell receptor repertoire breadth before novel antigen exposure; initiate 4 weeks before scheduled vaccination)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (4 weeks before vaccination) | 10mg 1x daily | Full standard course beginning 4 weeks before scheduled vaccination date. Goal is to maximize circulating naive T-cell numbers and TCR repertoire diversity before antigen challenge. Most relevant for elderly subjects (65+) or immunosenescent subjects where influenza, pneumococcal, herpes zoster, or COVID-19 vaccine seroconversion rates are suboptimal. |
| Days 1-5 (1 week post-vaccination) | 5mg 1x daily | Post-vaccination consolidation half-dose course. Supports the expanding antigen-specific T-cell clonal response during the 7-14 day consolidation window following vaccination. Strengthens the T-cell memory formation phase. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4: Post-Chemotherapy Immune Reconstruction Protocol (Goal: systematic thymic restoration following chemotherapy-induced lymphopenia and bone marrow suppression; minimum 4 weeks post-chemotherapy with ANC recovery confirmed before initiating)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x daily | Ultra-conservative entry. ANC must be > 1.0 × 10⁹/L before initiating. Platelet count > 75 × 10⁹/L. Requires oncology/hematology supervision. The involuted thymus emerging from chemotherapy-mediated lymphodepletion requires gradual re-stimulation to avoid excessive immune activation before marrow recovery is consolidated. |
| Weeks 3-4 | 2mg 1x daily | Dose escalation. CBC weekly monitoring. Continue if ANC trending upward. |
| Weeks 5-8 | 5mg 1x daily | Mid-dose phase. Lymphocyte subset panel at week 6 to document T-cell recovery progress. |
| Weeks 9-12 | 10mg 1x daily | Full standard dose. Initiate only when ANC > 1.5 × 10⁹/L and CD4+ trending toward 200+. Combine with Thymosin Alpha-1 from week 9 for simultaneous T-cell activation support alongside thymic output restoration. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 5: Khavinson Longevity Stack: Thymalin + Epithalon + Crystagen Sequential Protocol (Goal: replicate the multi-axis thymic/telomeric/peripheral-immune intervention structure that produced the Khavinson mortality outcome data; thymic restoration followed by telomere protection followed by peripheral immune normalization)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg Thymalin 1x daily + 5mg Epithalon SC at bedtime | Concurrent Thymalin and Epithalon. Thymalin at any time of day; Epithalon at bedtime. This precisely mirrors the core structure of the Khavinson longevity studies that demonstrated 28-45% all-cause mortality reduction. Baseline immune panel, telomere length, and biological age assessment before initiating. |
| Days 11-20 | 5mg Epithalon SC at bedtime (Thymalin course complete) | Thymalin standard 10-day course is complete. Continue Epithalon for its full 20-day course. The newly thymopoietically restored immune system during Days 11-20 coincides with continued TERT activation: the biological window where the newly exported naive T-cells encounter Epithalon's circadian/telomeric normalization. |
| Days 21-30 | Crystagen 500mcg-2mg SC 1x daily (begin Crystagen standard course) | Sequential peripheral immune normalization with Crystagen immediately following Epithalon completion. Crystagen normalizes peripheral T-cell and NK cell functional programs in the newly expanded naive T-cell population that Thymalin produced. The sequential structure: thymic output (Thymalin) → telomere protection (Epithalon) → peripheral immune normalization (Crystagen): provides comprehensive immune aging intervention across all three levels. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Thymus); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Organ transplant recipients: Thymalin's thymic restoration and T-cell education activity directly counteracts the immunosuppressive regimens required to prevent allograft rejection; thymic peptide delivery in the context of transplant immunosuppression creates acute rejection risk; absolute contraindication. Limited / unverified
- Active autoimmune disorders with significant T-cell-mediated pathology (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Type 1 diabetes): Thymalin increases naive T-cell output and T-cell activation; in conditions where pathological T-cells are already attacking self-tissue, restoring immune competence without correcting the autoimmune drive may amplify tissue destruction. Limited / unverified
- Active graft-versus-host disease: T-cell expansion and activation in the context of GVHD is dangerous. Limited / unverified
- Concurrent immunosuppressive therapy (calcineurin inhibitors, high-dose corticosteroids, mycophenolate): the fundamental pharmacological opposition between Thymalin's immunorestorative activity and immunosuppressive drugs makes combined use counterproductive and potentially destabilizing. Limited / unverified
- Active hematological malignancy involving T-cell lineages (T-cell lymphoma, T-cell leukemia): Thymalin's T-cell education and expansion activity could stimulate malignant T-cell proliferation. Limited / unverified
- Known hypersensitivity to Thymalin, bovine thymic extracts, or excipients. Limited / unverified
- Pregnancy: thymic peptide immunomodulation during fetal immune system development is not established as safe. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
Side effects (limited evidence)
- Injection site redness and mild erythema: the most commonly reported adverse effect; rare given Thymalin's exceptional tolerability profile; self-resolving. Limited / unverified
- Mild transient fatigue: occasionally reported in the first 2-3 days of the 10-day course; related to thymic activation and immune response initiation. Limited / unverified
- Low-grade fever: uncommon; associated with the initial immune activation cascade; typically resolves within 48 hours. Limited / unverified
- Mild flu-like symptoms: rare; consistent with early immune activation; self-limiting. Limited / unverified
- Temporary lymphocyte redistribution: a pharmacodynamic effect rather than an adverse event; circulating lymphocytes may transiently decrease before the new naive T-cell output increases peripheral counts; not clinically significant in immunocompetent subjects. Limited / unverified
- Theoretical autoimmune exacerbation: in subjects with subclinical autoimmune predisposition; the immune competence restoration from Thymalin could unmask previously suppressed autoimmune activity. Limited / unverified
- No documented endocrine disruption, HPA axis effects, or hormonal side effects: Thymalin's activity is confined to the thymic/immune system axis. Limited / unverified
- No documented tachyphylaxis: the twice-yearly protocol maintains efficacy across multiple years of administration without diminishing returns in the published Russian clinical literature. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.